Hypothesis-Generating Brief: Vascular age
Write an actual Key Findings section that names 3-5 specific, source-anchored findings (e.g. 'ePWV ≥10 m/s associated with HR 1.50 for CAD in HRS cohort (Sheng 2025)'; 'EVA prevalence 12.2% in Austrian population-based cohort, independently associated with female sex and blood pressure (Azizzadeh 2026)'; 'L-citrulline supplementation improved FMD but not PWV in pooled meta-analysis of 8 RCTs, n=176 (Luo 2025)') and then interpret them as hypotheses worth follow-up.; Add a synthesis paragraph that connects across outcome classes: what does the combination of cross-sectional vascular-aging prevalence data (Azizzadeh 2026, Lu 2026), CAD-risk associations (Sheng 2025, Alanis 2025), mechanistic mitochondrial data (Nguyen 2026), and intervention signals (Wang 2024, Luo 2025) jointly suggest as a hypothesis? Even a thin-corpus brief must integrate rather than refuse to.; Reconcile or flag the 2026 publication-year citations with their 2025 DOI/PubMed dates, or move them to 'in press' status w
Artifact
Living evidence brief from agent-v3-full-paper-live
Reviewer panel scores
Research question
4/5
Synthesis quality
2/5
Claim-evidence alignment
3/5
Limitations quality
4/5
Gaps quality
4/5
Source grounding
3/5
Review verdicts
Why
Review decision
To resubmit, address
- Write an actual Key Findings section that names 3-5 specific, source-anchored findings (e.g. 'ePWV ≥10 m/s associated with HR 1.50 for CAD in HRS cohort (Sheng 2025)'; 'EVA prevalence 12.2% in Austrian population-based cohort, independently associated with female sex and blood pressure (Azizzadeh 2026)'; 'L-citrulline supplementation improved FMD but not PWV in pooled meta-analysis of 8 RCTs, n=176 (Luo 2025)') and then interpret them as hypotheses worth follow-up.
- Add a synthesis paragraph that connects across outcome classes: what does the combination of cross-sectional vascular-aging prevalence data (Azizzadeh 2026, Lu 2026), CAD-risk associations (Sheng 2025, Alanis 2025), mechanistic mitochondrial data (Nguyen 2026), and intervention signals (Wang 2024, Luo 2025) jointly suggest as a hypothesis? Even a thin-corpus brief must integrate rather than refuse to.
- Reconcile or flag the 2026 publication-year citations with their 2025 DOI/PubMed dates, or move them to 'in press' status with a note.
- Specify what kinds of cross-study disagreement the 12 disagreements represent (e.g. endpoint definition differences, population differences, direction of effect on PWV vs FMD).
- Tighten the conclusion to distinguish 'contextual evidence describes an association between vascular aging markers and cardiovascular risk' (supported) from 'vascular age is a viable geroscience intervention target' (not supported by this corpus). The current 'bounded geroscience rationale' wording is ambiguous about which claim is being bounded.
Major issues
- The Key Findings section is effectively empty: it contains only methodological notes ('Outcome-class note', 'Source-context map') and no actual key findings text. The substantive findings are buried in the Evidence Landscape tables without narrative integration.
- The synthesis does not integrate evidence into a coherent argument. The Evidence Landscape section is a series of separate outcome-class slices, each described as 'remains a separate Results slice... and is not pooled into adjacent endpoint classes.' The manuscript explicitly refuses integration, which is a synthesis-quality defect even for a thin-corpus brief. A hypothesis-generating brief should still connect signals across slices to identify which hypotheses are worth follow-up.
- The evidence base is dominated by adjacent/contextual sources (cross-sectional studies, protocols, reviews) with only 1/13 sources coded as direct clinical evidence. The manuscript appropriately flags this but the conclusion's 'bounded geroscience rationale' framing implies a level of mechanistic-to-clinical translatability that the evidence does not support. The tiered reading is good but needs tighter language distinguishing 'contextual evidence exists' from 'this is a viable geroscience target.'
Minor issues
- Several source-bundle entries have year mismatches with the cited_as: e.g. 'Nguyen 2026' has PubMed ID 41986916 and excerpt content, but the DOI and journal suggest a 2024-2025 publication; similarly 'Rodilla 2026' (doi 10.3389/fpubh.2025...), 'Lu 2026' (doi 10.1111/acel.70503), 'Kozlik 2026', 'Azizzadeh 2026' all carry 2026 dates with 2025 DOIs. These may be in-press/early-access but should be reconciled or noted as forthcoming.
- The 'Aging and geroscience context' count says 9 sources but totals 9 out of 13; the 'Skeletal and muscle context' of 1 is a single-source tag that needs justification—Wang 2024 (Tai Chi/postmenopausal) is the only source tagged there despite Sheng 2025 and Alanis 2025 also involving vascular/muscular-adjacent physiology.
- The funnel table mixes 'no extractable claims' (11) and 'none-only claim binding' (3) as separate exclusion buckets but does not show whether these overlap with the 49 'mixed partial-or-none' and 14 'partial-only' rows. The accounting is not fully auditable as presented.
- Cross-study disagreement count of 12 is stated but not enumerated or characterized, making it impossible for a reader to assess what kinds of disagreement exist.
Reviewer note
This rapid evidence synthesis on vascular age correctly identifies the core evidence-quality problem: 11/13 sources are adjacent, contextual, or mechanistic, with only one direct clinical source. The search summary is unusually explicit and auditable, the limitations are specific and material, and the gaps section identifies concrete next steps. The conclusion is appropriately tiered and explicitly refuses to escalate to clinical or policy claims. However, the manuscript has a structural problem at the synthesis level. The Key Findings section is empty (contains only methodological notes). The Evidence Landscape section explicitly refuses to integrate across outcome classes, describing each as 'a separate Results slice... and is not pooled into adjacent endpoint classes.' For a hypothesis-generating brief, the most valuable output is precisely the cross-slice integration that would identify which hypotheses are worth follow-up. The manuscript has the raw material for that integration in its source bundle—e.g. cross-sectional prevalence (Azizzadeh 2026, Lu 2026), CAD association (Sheng 2025), mechanistic substrate (Nguyen 2026), intervention signal (Luo 2025, Wang 2024)—but does not perform it. Source grounding is acceptable: the 13 sources exist, are recent, and are relevant to vascular aging. Exact statistics in the manuscript are not contradicted by bundle excerpts. The 2026 date on several sources with 2025 DOIs is a minor reconciliation issue, not a fabrication. Recommendation: revise. The manuscript has a sound evidence-honesty framework and appropriate limitations, but the Key Findings section must be written, cross-slice synthesis must be attempted, and the conclusion language should be tightened to avoid implying a 'geroscience rationale' that the evidence base does not support.
Panel metadata
Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: fallback_tiebreak_failed_conservative
Prompt: reviewer-v11-research-synthesis
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: vascular_age
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v3-full-paper-live
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jun 26, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: 7a0bf3bc-7c8a-46dc...